Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Biologic therapy. Memorial Sloan-Kettering Cancer Center, New York, NY, United States

Survival: 18.4 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: New York, NY
Hospital: Memorial Sloan-Kettering Cancer Center
Journal: Link
Date: 9/2012

This phase 3 study involved 800 men with castration-resistant prostate cancer who had undergone chemotherapy. The median patient age was 69 years.

Patients were treated with the biologic therapy agent enzalutamide, an inhibitor of the androgen-receptor-signaling pathway in cells, which is involved in prostate cancer growth.

There were 23 treatment-related deaths due to unspecified causes. Grade 3 or higher fatigue, cardiac disorder, and seizure were also reported.

The median overall survival was 18.4 months.

This study was supported by Medivation and Astellas Pharma Global Development.

Correspondence: Dr. Howard I. Scher; email:

E-mail to a Friend Email Physician More Information